AU2011285532B2 - Processes for preparing tubulysins - Google Patents

Processes for preparing tubulysins Download PDF

Info

Publication number
AU2011285532B2
AU2011285532B2 AU2011285532A AU2011285532A AU2011285532B2 AU 2011285532 B2 AU2011285532 B2 AU 2011285532B2 AU 2011285532 A AU2011285532 A AU 2011285532A AU 2011285532 A AU2011285532 A AU 2011285532A AU 2011285532 B2 AU2011285532 B2 AU 2011285532B2
Authority
AU
Australia
Prior art keywords
compound
formula
optionally substituted
alkyl
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011285532A
Other languages
English (en)
Other versions
AU2011285532A1 (en
Inventor
Michael Groaning
Paul Joseph Kleindl
Christopher Paul Leamon
Allen Ritter
Hari Krishna R. Santhapuram
Katheryn Marie Stanford
Iontcho Radoslavov Vlahov
Yu Wang
Le-Cun Xu
Fei You
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of AU2011285532A1 publication Critical patent/AU2011285532A1/en
Priority to AU2013203491A priority Critical patent/AU2013203491A1/en
Application granted granted Critical
Publication of AU2011285532B2 publication Critical patent/AU2011285532B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2011285532A 2010-08-06 2011-08-05 Processes for preparing tubulysins Ceased AU2011285532B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013203491A AU2013203491A1 (en) 2010-08-06 2013-04-10 Processes for preparing tubulysins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37143310P 2010-08-06 2010-08-06
US61/371,433 2010-08-06
PCT/US2011/046797 WO2012019123A1 (en) 2010-08-06 2011-08-05 Processes for preparing tubulysins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013203491A Division AU2013203491A1 (en) 2010-08-06 2013-04-10 Processes for preparing tubulysins

Publications (2)

Publication Number Publication Date
AU2011285532A1 AU2011285532A1 (en) 2013-02-21
AU2011285532B2 true AU2011285532B2 (en) 2015-09-10

Family

ID=45559842

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011285532A Ceased AU2011285532B2 (en) 2010-08-06 2011-08-05 Processes for preparing tubulysins

Country Status (12)

Country Link
US (3) US8889880B2 (enExample)
EP (1) EP2600866A4 (enExample)
JP (1) JP2013535220A (enExample)
KR (1) KR20130096712A (enExample)
CN (1) CN103140227B (enExample)
AU (1) AU2011285532B2 (enExample)
BR (1) BR112013003004A2 (enExample)
CA (1) CA2807511A1 (enExample)
EA (1) EA025471B1 (enExample)
MX (1) MX2013001402A (enExample)
SG (1) SG187728A1 (enExample)
WO (1) WO2012019123A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
EP2209374B1 (en) 2007-10-25 2014-12-03 Endocyte, Inc. Tubulysins and processes for preparing
US8889880B2 (en) 2010-08-06 2014-11-18 Endocyte, Inc. Processes for preparing tubulysins
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) * 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EA201590622A1 (ru) 2012-10-16 2015-10-30 Эндосайт, Инк. Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
WO2015113760A1 (en) * 2014-01-28 2015-08-06 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation
CA2943299A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Bispecific her2 antibodies
RU2715905C2 (ru) 2014-10-01 2020-03-04 МЕДИММЬЮН, ЭлЭлСи Способ конъюгации полипептида
KR20170137725A (ko) * 2015-02-25 2017-12-13 윌리엄 마쉬 라이스 유니버시티 데스아세톡시투불리신 h 및 이의 유사체
PL3374398T3 (pl) 2015-11-10 2020-08-24 Medimmune, Llc Cząsteczki wiążące swoiste dla ASCT2 i ich zastosowanie
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
RU2018128784A (ru) 2016-01-27 2020-02-27 МЕДИММЬЮН, ЭлЭлСи Способы получения антител с заданным профилем гликозилирования
CN109069633A (zh) 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
UA126813C2 (uk) 2017-08-01 2023-02-08 Медімм'Юн, Ллк Моноклональний кон’югат антитіло-лікарський засіб до bcma
US11274124B2 (en) 2017-11-29 2022-03-15 William Marsh Rice University Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
CN116829592A (zh) 2020-09-11 2023-09-29 免疫医疗有限公司 治疗性b7-h4结合分子
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
KR20240099430A (ko) 2021-11-10 2024-06-28 아스트라제네카 아베 항체 분자 및 접합체
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
KR20240159839A (ko) 2022-03-09 2024-11-06 아스트라제네카 아베 FRα에 대한 결합 분자
JP2025525410A (ja) 2022-06-27 2025-08-05 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮成長因子受容体チロシンキナーゼ阻害剤を伴う組み合わせ
TW202448517A (zh) 2023-02-16 2024-12-16 瑞典商阿斯特捷利康公司 用治療性結合分子治療癌症的組合療法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
EP1521769B1 (de) 2002-07-09 2015-09-09 Dömling, Alexander Tubulysinkonjugate
US7816377B2 (en) 2002-07-09 2010-10-19 R&D-Biopharmaceuticals Gmbh Tubulysin analogues
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
US7601332B2 (en) 2003-01-27 2009-10-13 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
DE102009032972A1 (de) 2009-07-14 2011-01-20 Erbe Elektromedizin Gmbh Vorrichtung zur Herstellung von Anastomosen
WO2011069116A1 (en) 2009-12-04 2011-06-09 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
CA2790577A1 (en) 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US8889880B2 (en) * 2010-08-06 2014-11-18 Endocyte, Inc. Processes for preparing tubulysins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PELTIER, H.M. et al. "The Total Synthesis of Tubulysin D" Journal of the American Chemical Society (2006) Vol 128 pages 16018 to 16019 *
WU, S.-H. et al. "Enhancing the Enantioselectivity of Candida Lipase Catalyzed Ester Hydrolysis via Noncovalent Enzyme Modification" Journal of the American Chemical Society (1990) Vol.112 pages 1990 to 1995 *

Also Published As

Publication number Publication date
US20160177363A1 (en) 2016-06-23
CA2807511A1 (en) 2012-02-09
US8889880B2 (en) 2014-11-18
KR20130096712A (ko) 2013-08-30
EP2600866A4 (en) 2013-12-11
US9499849B2 (en) 2016-11-22
EA201390203A1 (ru) 2013-08-30
EA025471B1 (ru) 2016-12-30
JP2013535220A (ja) 2013-09-12
MX2013001402A (es) 2013-08-29
US20130137139A1 (en) 2013-05-30
US9273091B2 (en) 2016-03-01
HK1185558A1 (zh) 2014-02-21
WO2012019123A1 (en) 2012-02-09
CN103140227A (zh) 2013-06-05
CN103140227B (zh) 2016-01-20
EP2600866A1 (en) 2013-06-12
BR112013003004A2 (pt) 2016-06-14
AU2011285532A1 (en) 2013-02-21
SG187728A1 (en) 2013-03-28
US20150225447A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
US8889880B2 (en) Processes for preparing tubulysins
EP2831059B1 (en) Processes for preparing tubulysin derivatives and conjugates thereof
US9771391B2 (en) Process for preparing tubulysins
TW202313567A (zh) 作為抗病毒劑之蛋白酶抑制劑
FR2663336A1 (fr) Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
TW201625521A (zh) 類胡蘿蔔素衍生物、其藥理學上可容許之鹽或者其藥理學上可容許之酯類或醯胺類
CN115536716B (zh) 两性霉素b半合成衍生物及其制备方法和用途
CA3259556A1 (en) COMPOUNDS FOR THE TREATMENT OF CORONAVIRUS INFECTION
DE69610145T2 (de) Benzo-kondensierte Azepinon-und Piperidinonverbindungen, nützlich als ACE-und NEP-Inhibitoren
JP6890865B1 (ja) 狂犬病治療のための環状アミド化合物およびその方法
MXPA06000294A (es) Compuestos que tienen actividad contra el virus de la hepatitis c y procedimiento para producirlo.
EP0178980A1 (fr) Dérivés de céphalosporines, procédé d'obtention et leur application à titre d'antibiotiques
AU2002312656B2 (en) Peptoid compounds
AU2013203491A1 (en) Processes for preparing tubulysins
CN117769541A (zh) 作为抗病毒剂的蛋白酶抑制剂
HK1185558B (en) Processes for preparing tubulysins
CA3018344C (en) Neuropeptide s receptor (npsr) agonists
EP0467280B1 (en) Novel spergualin-related compound and use thereof
FR2801591A1 (fr) Derives macrocycliques de l'acide hydroxamique, leur preparation et les compositions qui les contiennent
WO2007067906A2 (en) Peptide deformylase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired